Metagenomi Technologies, a startup developing treatments for genetic diseases backed by Moderna Therapeutics Inc (NASDAQ:MRNA) and Bayer AG (ETR:BAYN, OTC:BAYZF), filed for a US IPO on Friday.
Founded in 2018 by scientists at UC Berkeley, Metagenomi’s revenue to date has come from a trio of collaborations, including one with backer Moderna.
For the period ended September 30, the company saw revenue of $32.36 million, nearly triple what it generated in the year-ago quarter. Its loss was $48.96 million, compared to $28.97 million a year earlier.
The company raised $275 million in a private funding round a year ago, according to reports.
Now, Metagenomi plans to list on the Nasdaq under the ticker symbol MGX.